Cells were incubated with fluorescence-labeled antibodies in 4 C for 30 min. demonstrated degrees of apoptotic cells just like those of PBS-treated cells. Furthermore, bvPLA2 treatment increased expression of anti-apoptotic substances including PD-1 and CTLA-4. The survival price elevated in bvPLA2-treated Tregs. Our results reveal that bvPLA2-mediated modulation of apoptotic signaling is certainly highly associated with the Treg induction, which exhibits protective effects against various immune-related diseases. To our knowledge, this study is the first to demonstrate that bvPLA2 is the major bee venom (BV) compound capable of inducing Treg expansion through altering apoptotic signal. L.) which contains a variety of enzymes, biologically active amines, peptides, and non-peptide components. The two major compounds in BV are melittin and phospholipase A2 (bvPLA2). Melittin is a cationic cell-lytic peptide consisting of 26 amino acids, and bvPLA2 is an enzyme which hydrolyzes membrane phospholipids. Bee venom therapy (BVT) consists in using BV for therapeutic purposes via injection by either stings from live bees or acupuncture needles. BVT has recently been widely used as an alternative therapy for the clinical treatment of a number of diseases, including rheumatoid arthritis and Parkinsons disease (PD) [1,2]. The anti-apoptosis, anti-fibrosis, and anti-inflammatory effects of BVT have been known for centuries and demonstrated in several reports and research articles [3,4,5]. However, adverse effects of BVT including skin problems, systemic reactions, and nonspecific reactions have also been reported. Furthermore, the Mouse monoclonal to CD41.TBP8 reacts with a calcium-dependent complex of CD41/CD61 ( GPIIb/IIIa), 135/120 kDa, expressed on normal platelets and megakaryocytes. CD41 antigen acts as a receptor for fibrinogen, von Willebrand factor (vWf), fibrinectin and vitronectin and mediates platelet adhesion and aggregation. GM1CD41 completely inhibits ADP, epinephrine and collagen-induced platelet activation and partially inhibits restocetin and thrombin-induced platelet activation. It is useful in the morphological and physiological studies of platelets and megakaryocytes.
mechanisms underlying its therapeutic effect are yet to be elucidated. The enzyme bvPLA2 is a disulfide-rich enzyme that catalyzes the hydrolysis of the sn-2 ester bond of phospholipids, which leads to the release of arachidonic acid and lysophospholipids; bvPLA2 is part of the group III secretory PLA2 (sPLA2), and its catalytic activity is necessary to initiate the IgE response in rodent mast cells [6]. Moreover, bvPLA2 is a potent inducer of T helper type 2 (Th2) immune reactions and the activation of group 2 innate lymphoid cells (ILC2) through the release of IL-35 [7]. Recently, numerous studies have reported the protective effects of bvPLA2 against a variety of diseases, including Alzheimers disease, allergic asthma, and cisplatin-induced organ inflammation [8,9,10]. Chung et al. revealed that bvPLA2 binds to a mannose receptor (CD206) or a C-type lectin on dendritic cells (DC) and increases the expression of prostaglandin E2 D-AP5 (PGE2), which binds to EP2 receptors on na?ve T helper cells and leads to the differentiation into CD4+CD25+Foxp3+ regulatory T cells (Tregs) [11]. The induction of Treg populations by bvPLA2 treatment contributes to immune suppression in various immune disease-related models [8,12]. Tregs are a specialized population of T cells for which the essential role is to maintain immune homeostasis and self-tolerance. Tregs are divided into three different types depending on the expression level of CD62L and CD127: resting Tregs (CD62LhiCD127low), activated effector Tregs (CD62LlowCD127low), and memory Tregs (CD62LlowCD127hi) [13]. Tregs have been shown to play a D-AP5 crucial role in the normal immune system for the establishment D-AP5 and maintenance of immunologic self-tolerance and immune homeostasis [14,15,16]. Adoptive transfer of ex vivo expanded CD4+CD25+ Tregs prevents pathology in various mouse models including graft versus host disease (GvHD) [17,18], and GvHD was the first disease to be tried in translation studies in humans. The clinical trial actually involved mainly stem cell transplantation (SCT), solid organ transplantation, and autoimmune diseases [19]. While previous studies implicated Tregs as an important constituent of the immune system for the maintenance of self-tolerance [14,15,16,20], a recent study further indicated that systemic administration of Tregs attenuates the progression of Alzheimers disease (AD) and could be an effective treatment [21]. In light of this finding, modulation of the Treg cells expansion has been proposed as a potential treatment for neuroinflammation-mediated diseases such as Parkinsons disease and amyotrophic lateral sclerosis [22,23]. For the.